TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04157088
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160mg, once daily
Study: NCT00414908
Drug: Pancrelipase delayed release capsule
Normalized name: Pancrelipase Delayed-Release Capsules
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24,000 unit capsule
Study: NCT01492504
Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
Study: NCT01951417
Drug: Adapalene/BPO Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
Study: NCT05264493
Drug: Naloxone Hydrochloride Injection, USP
Normalized name: NALOXONE HYDROCHLORIDE 10 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Naloxone Hydrochloride Injection, USP, Auto-Injector]
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg IM (2mg/2 mL) injection into gluteal muscle
Study: NCT05264493
Drug: Naloxone Hydrochloride Injection, USP
Normalized name: NALOXONE HYDROCHLORIDE 10 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Naloxone Hydrochloride Injection, USP, Auto-Injector]
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg bolus IV (2mg/2 mL)
Study: NCT00727935
Drug: Lidocaïne
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02610712
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00097370
Drug: mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study Drug
Study: NCT03742986
Drug: Nivolumab 360mg
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
Study: NCT00721331
Drug: nortriptyline HCl + loratadine
Normalized name: Nortriptyline Hydrochloride
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical
Study: NCT00721331
Drug: nortriptyline HCl
Normalized name: nortriptyline HCl
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical
Study: NCT00721331
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical
Study: NCT00721331
Drug: Active ingredient free vehicle cream of CRx-197
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT02385617
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study: NCT03742986
Drug: Paclitaxel 80mg/m^2
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
Study: NCT03742986
Drug: Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)
Study: NCT03742986
Drug: Trastuzumab 8mg/kg and 6 mg/kg
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
Study: NCT03742986
Drug: Pertuzumab 840mg and 420mg
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
Study: NCT04346199
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib- administered orally
Study: NCT03066830
Drug: Sotagliflozin (SAR439954)
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03066830
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00045799
Drug: Omeprazole sodium bicarbonate immediate release PWD/FS
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00045799
Drug: Cimetidine IV
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04425993
Drug: Isosorbide Dinitrate 5 MG
Normalized name: isosorbide dinitrate 5 MG
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
Study: NCT02635282
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02635282
Drug: intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01843075
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily subcutaneous injection
Study: NCT02881177
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 IU
Study: NCT00223002
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sample collected at time of procedure and then analysed for bacterial contamination
Study: NCT03893955
Drug: ABBV-927
Normalized name: Anti-cd40 agonist monoclonal antibody abbv-927
DrugBank: Giloralimab (DB18862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT03893955
Drug: ABBV-368
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT03893955
Drug: ABBV-181
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT03893955
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT03893955
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT00753675
Drug: ZD6474, Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT00753675
Drug: ZD6474, Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT00753675
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT02300870
Drug: Optison
Normalized name: Optison
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiogram with IV contrast
Study: NCT01136252
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
Study: NCT00446017
Drug: adrenaline
Normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00446017
Drug: milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02573259
Drug: PF-06801591
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV every 21 days (Part 1)
Study: NCT02573259
Drug: PF-06801591
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SC every 28 days (Part 1 and 2)
Study: NCT03568578
Drug: Entecavir 0.5 mg
Normalized name: entecavir 0.5 MG
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
Study: NCT02089048
Drug: Auranofin
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
Study: NCT03669601
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nucleoside metabolic inhibitor.
Study: NCT00204321
Drug: sirolimus (drug), mmf (drug)
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00080353
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080353
Drug: gp100:209-217
Normalized name: Gp100:209-217(210m) peptide
DrugBank: Disomotide (DB17469)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080353
Drug: OKT3
Normalized name: Humanized OKT3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080353
Drug: Montanide ISA 51
Normalized name: Montanide ISA 51
DrugBank: Incomplete Freund's adjuvant (DB17475)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04601675
Drug: Ranibizumab Ophthalmic and Intravitreal Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
Study: NCT04601675
Drug: Ranibizumab Ophthalmic only
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
Study: NCT04593043
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin dispensing claim is used as the reference
Study: NCT04593043
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dispensing claim is used as the exposure
Study: NCT00369343
Drug: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
Study: NCT00908271
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
Study: NCT03832647
Drug: Salicylic Acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic Acid
Study: NCT00461825
Drug: Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090909
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00090909
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00090909
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02021214
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01945944
Drug: Placebo (0.9% saline)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mL of normal saline given via nebulizer every 6hrs
Study: NCT00526318
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00526318
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00526318
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526318
Drug: vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02154438
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
Study: NCT03912740
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
Study: NCT03912740
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
Study: NCT00807365
Drug: GHRH
Normalized name: GHRH
DrugBank: Tesamorelin (DB08869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
Study: NCT00039390
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01956253
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 240 mg orally once daily
Study: NCT00008359
Drug: caspofungin acetate
Normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00008359
Drug: liposomal amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00508911
Drug: COC
Normalized name: Cocet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
Study: NCT00954187
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
Study: NCT00954187
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg PO TID
Study: NCT00490971
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
Study: NCT03245151
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
Study: NCT03245151
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension
Study: NCT00490971
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
Study: NCT04142359
Drug: N-803 alone
Normalized name: (+/-)-N-methylephedrine
DrugBank: DL-Methylephedrine (DB11278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-803 alone
Study: NCT02021461
Drug: ESL Banana taste
DrugBank: Banana (DB10505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study: NCT03829475
Drug: Bezlotoxumab
Normalized name: Bezlotoxumab
DrugBank: Bezlotoxumab (DB13140)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
Study: NCT03829475
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
Study: NCT04303416
Drug: Albumin solution
Normalized name: darbepoetin alfa in albumin solution
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasma exchange with albumin, one per week for one month, then one per month for 5 months
Study: NCT02204332
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00593450
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: • 0.5 mg (0.05 mL)intravitreal injection
Study: NCT00593450
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: • 1.25 mg (0.05 mL)intravitreal injection
Study: NCT04500249
Drug: rescue IA
Normalized name: magnesium aluminum silicate type Ia
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
Study: NCT01526785
Drug: Alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
Study: NCT02789969
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone 15mcg/kg IV
Study: NCT00369252
Drug: Nimotuzumab (TheraCIM h-R3)
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01628562
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol 50 mcg/kg/min
Study: NCT00847418
Drug: esketamine hydrochloride
Normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02007720
Drug: Serelaxin
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02450045
Drug: 0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00957177
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg pregabalin orally 1 hour before operation
Study: NCT03127319
Drug: apatinib docetaxel zoledronic
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT03127319
Drug: docetaxel zoledronic
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT03860038
Drug: TJ202 and Dexamethasone
Normalized name: Ciprofloxacin and Dexamethasone Otic Suspension
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
Study: NCT02898077
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02898077
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT01638429
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin: 500mg po bid for 10 days
Study: NCT01638429
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin: 550mg po tid for 10 days
Study: NCT02703181
Drug: Epelsiban (GSK557296)
Normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
Study: NCT01419535
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 50mg tablet by mouth every six hours for nine days.